Syros Goes For Reboot With New Investors And Leukemia Licensing
Bain Capital Leads $90.5m Investment
Syros has failed to progress in its leukemia niche since its launch a few years ago, but a new drug candidate and funding could revive its fortunes.
You may also be interested in...
Gene-expression focused Syros adds about $190m to its coffers with Tyme merger and PIPE financing. This will get it past pivotal data for tamibarotene and enable Phase III development of a leukemia candidate.
Beam is the latest allogeneic CAR-T developer to face a regulatory hold-up, but other candidates using its pioneering base-editing technology are now progressing.
AstraZeneca’s momentum is growing towards ‘industry-leading' revenue growth, but investors are focused on the operating margin, and concerned about when CEO Pascal Soriot will depart.